trending Market Intelligence /marketintelligence/en/news-insights/trending/BAXQFVP5gonjr67cahzncg2 content esgSubNav
In This List

US FDA approves Glenmark's generic hypertension drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA approves Glenmark's generic hypertension drug

Glenmark Pharmaceuticals Ltd. secured the U.S. Food and Drug Administration approval to market a generic version of Benicar.

Benicar is Daiichi Sankyo Co. Ltd.'s hypertension drug, and Glenmark will manufacture it at its facility in Goa, India.

Benicar generated $950 million in sales during the 12 months ending March, according to IMS Health data.